Gdru.Bo

GDRU.BO maintains a capital structure with a debt-to-equity ratio of 1.48, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.08, suggesting limited short-term liquidity cushion. Free cash flow is negative at -131.7 million INR, while capital expenditures amount to -199.98 million INR, reflecting ongoing investment in long-term assets.

Profitability metrics show a return on equity of 10.1% and a return on assets of 3.06%, both below the industry median for Pharmaceuticals, which typically exceeds 12% ROE and 5% ROA. Operating income of 93.8 million INR and net income of 43.8 million INR indicate a relatively narrow margin profile compared to peers.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks.

Outlook for the current fiscal year shows a projected revenue growth of 4.5%, with a 2.1% increase in operating income. For the next fiscal year, revenue is expected to grow by 3.8%, with a 1.9% increase in operating income. These growth rates are below the industry median of 6.2% revenue growth and 4.5% operating income growth.

Risk assessment highlights a medium liquidity risk due to a current ratio of 1.08 and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant dilution sources identified in the latest filings. The company has not disclosed any recent equity offerings or ATM facilities that would suggest imminent dilution pressure.

Recent events include the filing of the latest annual report, which outlines the company's strategic focus on expanding its product portfolio and enhancing R&D capabilities. No material earnings call transcripts or regulatory filings have been disclosed in the past quarter that would suggest significant operational or strategic shifts.